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Background: Serum phosphorus control is critical for chronic kidney disease (CKD) 5D patients. Currently, clinical
profile for an oral phosphorus binder in the mainland Chinese population is not available.
Objective: To establish the efficacy, safety, and tolerability of lanthanum carbonate in CKD 5D patients.
Design: Multicenter, randomized, double blind, placebo-controlled study. A central randomization center used
computer generated tables to allocate treatments.
Setting: Twelve tertiary teaching hospitals and medical university affiliated hospitals in mainland China.
Participants: Overall, 258 hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) adult patients were enrolled.
Intervention: After a 0–3-week washout period and a 4-week lanthanum carbonate dose-titration period, 230 patients
were randomized 1:1 to receive lanthanum carbonate (1500 mg-3000 mg) or placebo for a further 4-week
maintenance phase.
Main outcome measures: Efficacy and safety of lanthanum carbonate to achieve and maintain target serum
phosphorus concentrations were assessed.
Results: In the titration phase, serum phosphorus concentrations of all patients decreased significantly. About
three-fifths achieved target levels without significantly disturbing serum calcium levels. At the end of the maintenance
period, the mean difference in serum phosphorus was significantly different between the lanthanum carbonate and
placebo-treated groups (0.63±0.62 mmol/L vs. 0.15±0.52 mmol/L, P < 0.001). The drug-related adverse effects were
mild and mostly gastrointestinal in nature.
Conclusion: Lanthanum carbonate is an efficacious and well-tolerated oral phosphate binder with a mild AE profile in
hemodialysis and CAPD patients. This agent may provide an alternative for the treatment of hyperphosphatemia in
CKD 5D patients in mainland China.
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Hyperphosphatemia is highly prevalent in chronic kidney
disease (CKD) 5D patients undergoing hemodialysis and
peritoneal dialysis [1]. Uncontrolled hyperphosphatemia
contributes to the development of secondary hyperpara-
thyroidism, renal osteodystrophy, vascular calcification,
and a graded increase of all-cause mortality in dialysis
patients [2-6]. There is also an association between
increased phosphate levels, and mortality and cardiovas-
cular mortality risk [7,8]. The K/DOQI 2003 guidelines
recommend a target phosphatemia of 3.5–5.5 mg/dL
(1.21–1.78 mmol/L) in dialysis patients [9]. Despite dietary
restriction and adequate dialysis, 90% of dialysis patients
still need oral phosphate binders to control their phos-
phate levels and thereby reduce mortality [1,10,11].
Aluminum hydroxide used to be the mainstay of
phosphate-binding therapy but was largely abandoned
due to its systemic toxicity. Calcium-based phosphate
binders (carbonate or acetate) are the most commonly
used phosphate binders in contemporary practice, al-
though to date few randomized controlled trials (RCTs)
have examined their effect on improving prognosis and
decreasing mortality. Moreover, these phosphate binders
may cause hypercalcemia in ≤50% of treated patients,
leading to vascular calcification and higher death risk, es-
pecially when co-administered with vitamin D analogs
[3,4,12,13]. Sevelamer hydrochloride/carbonate is the first
synthetic non-calcium, non-aluminum phosphate binder
without the tendency to promote hypercalcemia. How-
ever, recent meta-analyses failed to establish comparative
superiority of sevelamer over calcium-based phosphate
binders [14,15]. Moreover, patients often require large
numbers of tablets to achieve phosphorus control.
The limitations of current treatments for hyperpho-
sphatemia underscore the need for safe and efficacious
calcium- and aluminum-free alternatives with low tablet
load. Lanthanum carbonate (FosrenolW) is a novel phos-
phate binder with similar therapeutic potency as
aluminum hydroxide but a more favorable safety profile.
Several RCTs have demonstrated lanthanum carbonate
to be an efficacious and well tolerated agent for phos-
phorus control with low tablet burden in CKD 5D
patients [16-20]. A double-blind RCT in 73 Chinese
patients on hemodialysis in Taiwan showed similar
results to previous US and European studies [17]. How-
ever, mainland China has more limited medical re-
sources and must serve a larger population of CKD 5D
patients across a broader territory than other major
regions of China, including Taiwan, which makes com-
prehensive treatment of these patients more difficult and
challenging [21]. Furthermore, there are currently no
officially approved phosphorus binders in mainland
China. Therefore, there is an urgent need to establish
evidence-based research on oral phosphate-binders toguide serum phosphorus control of CKD 5D patients in
mainland China.
To establish the clinical profile of lanthanum carbonate
in the mainland Chinese population and identify any dif-
ference from other countries, a multicenter, randomized,
double-blind study was conducted. The study assessed the
efficacy, safety, and tolerability of lanthanum carbonate to
achieve and maintain target serum phosphorus concentra-
tions in CKD 5D patients on hemodialysis or continuous
ambulatory peritoneal dialysis (CAPD). Changes in other
important parameters such as serum calcium and serum
parathyroid hormone (PTH) levels were also monitored.Methods
Patients
CKD 5D patients aged 18–70 years receiving hemodialysis
or CAPD for ≥3 months were eligible to participate.
Patients fulfilling any of the following criteria were ex-
cluded: 1) hypercalcemia (serum calcium >10.4 mg/dL
[>2.60 mmol/L]) or hypocalcemia (serum calcium <8.4
mg/dL [<2.10 mmol/L]); 2) severe hyperparathyroidism
(PTH >1000 pg/mL [>105.3 pmol/L]); 3) previous gastro-
intestinal (GI) surgery or ongoing GI dysfunction includ-
ing uncontrolled ulcer, inflammatory bowel diseases, or
GI bleeding in the past 6 months; 4) serum transaminases
or bilirubin >2.5 times the upper limit of normal (ULN);
5) severe heart failure (NYHA class III–IV); and 6) other
exclusion criteria included HIV-positive status, known
allergy to lanthanum, pregnant or lactating women, life-
threatening malignancy, and exposure to other experi-
mental drugs within 30 days before screening. All patients
were judged by the investigator to be compliant with the
study protocol. Treatment was carried out strictly in ac-
cordance with the trial protocol. Patients with poor com-
pliance or who failed to take medicine according to the
protocol were also excluded. One subject (SP315) did
not follow doctor’s orders and took α-keto acid tablets
(3 tablets per day, 50 mg calcium per tablet, stopped after
10 days medication) in the titration phase. Because this
occurred in the titration period, and a small dose of cal-
cium (150 mg/day) was taken, the subject was not
excluded.Study design
This was a phase III, randomized, double blind, placebo-
controlled, dose-titration trial in hemodialysis or CAPD
patients conducted simultaneously at 12 hospitals in main-
land China (Registration No. ChiCTR-TRC-10000817).
The study comprised three phases: screening and a
0–3-week washout period; a 4-week dose titration period;
and a 4-week double blind, placebo-controlled, rando-
mized, maintenance phase.
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A complete medical history and physical examination
were performed at the screening visit. Patients who had
not taken any phosphorus binders for 1 week before
screening could skip the washout period. Patients previ-
ously on phosphate binders (calcium, sevelamer), on the
other hand, discontinued them and underwent washout
over 0–3 weeks. Patients were put on a low-phosphorus
diet (800–1000 mg/d). The calcium concentration of
dialysis fluid and the mode of dialysis were kept con-
stant. Phosphorus levels were monitored at each weekly
visit. Patients whose serum phosphorus increased
to >5.5 mg/dL (>1.78 mmol/L) were eligible to enter
the dose-titration phase, while those whose phosphorus
levels remained ≤5.5 mg/dL (≤1.78 mmol/L) at the end
of week 3 of the washout period were withdrawn from
the study.
Phase 2: open-label dose titration
During the open-label dose-titration phase, all recrui-
ted patients received a starting daily dose of 1500 mg
lanthanum carbonate and could be uptitrated to
≤3000 mg/d as necessary to achieve and maintain serum
phosphorus ≤5.5 mg/dL (≤1.78 mmol/L, KDOQI 2003)
over 4 weeks [9]. Patients on hemodialysis were titrated
weekly, while those on CAPD were titrated every other
week. A standardized dose-titration regimen based on
serum phosphorus concentration was used. The dose of
lanthanum carbonate was uptitrated one level (500 mg)
in hemodialysis or two levels (1000 mg) in CAPD
patients at each visit, if the serum phosphorus target
level had not been achieved.
Phase 3: double-blind randomization and maintenance
treatment
At the end of the dose-titration phase, patients were ran-
domized 1:1 to receive lanthanum carbonate or placebo
for a further 4-week maintenance phase. Patients visited
once every 2 weeks. No dose adjustments were given
during this phase.
Efficacy and safety assessments
The primary efficacy measure was the serum phos-
phorus level at the end of the maintenance phase com-
pared with baseline (time of randomization). Secondary
evaluation parameters involved serum phosphorus levels
at each visit, proportion of patients with controlled
serum phosphorous levels or response to the experimen-
tal drugs (defined as a decrease in the serum phosphorus
level >25% from baseline) at the end of the maintenance
phase, and intact PTH (iPTH) level at the end of the ti-
tration and maintenance stage.
Demographic characteristics such as sex, age, and med-
ical history were collected at screening, whereas vital signsand concomitant medications were monitored throughout
the study. Serum calcium levels were examined at each
visit. Hematologic and biochemical parameters were mea-
sured at the end of each phase. Adverse events (AEs) and
serious adverse events (SAEs) were recorded throughout
the study.Statistical analysis
Assuming the mean difference of the serum phosphorus
level compared to randomization between lanthanum
carbonate and placebo to be −0.45 mmol/L, with a type
I error of 2.5%, a power of 80%, and 20% loss to follow-
up, it was calculated that about 120 patients per group
were needed to detect the estimated differences, among
whom 2/3 were hemodialysis patients, and 1/3 were
peritoneal dialysis patients.
A blind data review meeting that involved statisticians,
the data administrator, principal investigators, and the
sponsor was conducted to divide the study population.
According to the basic principles of intention-to-treat
(ITT) analysis, all subjects who were randomized and
had at least one record of drug administration and effi-
cacy evaluation after randomization were included in the
full analysis set (FAS) [22]. For the missing values of the
main indicators (phosphate levels), the last observation
carried forward (LOCF) estimation method was adopted
when analyzing the FAS. All subjects who completed the
treatment according to protocol or had no serious viola-
tions of the protocol were defined as the per-protocol
set (PPS). For efficacy endpoints, FAS and PPS were ana-
lyzed statistically as the analysis set. Taking the analysis
result of FAS as the main analysis result of the study and
referring to the PPS analysis result, discussion and ana-
lysis were undertaken when inconsistencies occurred.
For safety endpoints, the safety set (SS) was defined as a
patient receiving at least one medication. The results
were divided into titration and maintenance phases, and
safety analysis was performed on the corresponding SS.
For the primary efficacy analysis, serum phosphorus
from randomization to each visit of maintenance phase
was assessed by an analysis of covariance (ANCOVA)
model, and the 95%CI was calculated. The percent of
patients in each treatment group achieving target se-
rum phosphorus was calculated and compared by the
Cochran-Mantel-Haenszel test. The change in the serum
phosphorus level at each visit over the titration period was
examined. Continuous variables are expressed as means
(± standard deviation) or medians (range) as appropriate,
and they were compared by t-test or Wilcoxon rank-sum
analysis. Categorical variables are expressed as numbers
(percent) and were analyzed by the chi-squared test or
Fisher’s exact test. Two-sided P-values < 0.05 were consid-
ered statistically significant. All statistical procedures were
Xu et al. BMC Nephrology 2013, 14:29 Page 4 of 11
http://www.biomedcentral.com/1471-2369/14/29performed using SAS software (version 9.2, SAS Institute
Inc, Cary, NC).Ethics
The study was implemented in compliance with the
Declaration of Helsinki and approved by local ethics
committees at each of the participating centers. Written,
informed consent was obtained from all patients. The
full name of the overall 12 ethical committees that
granted approval for our study are as follows:
1. The ethics committee of Changzheng Hospital,
2. The ethics committee of First Affiliated Hospital of
Sun Yat-sen University,
3. The ethics committee of Jingling Hospital,
4. The ethics committee of First Affiliated Hospital of
China Medical University,













Figure 1 Study flow diagram.6. The ethics committee of Affiliated Hospital of
Nantong Medical College,
7. The ethics committee of Renji Hospital,
8. The ethics committee of People's Hospital of Peking
University,
9. The ethics committee of Xinqiao Hospital,
10. The ethics committee of Renmin Hospital of
Wuhan University,
11. The ethics committee of Chinese PLA General
Hospital,




A total of 258 consecutive patients entered the titration
phase (Figure 1). During this period, 28 patients were
withdrawn or excluded. The remaining 230 patients com-
pleted the titration phase and were randomized 1:1 into




Not meeting inclusion criteria (n=4)
Declined to participate (n=3)
Unendurable adverse effects (n=14)
Kidney tansplantation (n=2)
Not compliant with the study protocol judged 
by the investigator (n=3)
Transferred to other dialysis center (n=1)
Severe violation of study protocol (n=1)
Excluded  (n=2)
Severe adverse event: peritoneal dialysis 
associated peritonitis (n=1)
Loss of contact after randomization and 
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of them had validated efficacy evaluation after ran-
domization. Among these three patients, two were in the
control group. One had a cerebral infarction four days
after randomization; the other patient could not be con-
tacted by the investigator after randomization and was
defined as inappropriate to continue. The remaining
excluded patient was a peritoneal dialysis patient in the
lanthanum carbonate group who developed peritonitis 10
days after randomization and stopped the medication.
There was no significant difference in demographic fea-
tures between lanthanum carbonate and placebo-treated
patients (Table 1). Compliance with study treatment was
similar in the two treatment groups (lanthanum carbon-
ate, 92.9%; placebo, 94.6%; P = 0.59); for all patients, com-
pliance was 93.7%.Serum phosphorus
The mean serum phosphorus concentrations at each visit
during the study are summarized in Figure 2 and Table 2.
At the end of the washout period, the serum phosphorus
concentration for all patients was 2.41 mmol/L. During
dose titration with lanthanum carbonate, serum phos-
phorus concentration decreased; for patients assigned to
lanthanum carbonate and placebo treatment groups this
parameter was 1.64 and 1.71 mmol/L, respectively, at ran-
domization (P = 0.24). During the maintenance phase, the
mean serum phosphorus remained low for the lanthanum
carbonate group but was substantially increased in the
placebo group (Figure 2). Mean differences between the
two groups were significant throughout randomized treat-
ment (P < 0.001 at all time-points, Table 3). Compared
with baseline (time of randomization), variations in the








Post-dialysis weight (kg) 60
Dialysis mode Hemodialysis 82
Peritoneal dialysis 32
Hemodialysis frequency (per week) 2.
Hemodialysis time (hr) 4.
Total volume of peritoneal dialysate (ml) 79
Heart failure 4phase were significantly lower in patients treated with lan-
thanum carbonate than in those on placebo: 0.15 mmol/L
vs. 0.63 mmol/L (mean difference between groups of −0.48
[95% confidence interval (CI): -0.63, -0.33], P < 0.001).
After 4 weeks titration, 61.6% of patients had con-
trolled serum phosphorus levels. At the end of the
maintenance phase, compared with only 13.3% patients
in the placebo group, 57.9% patients in the lanthanum
carbonate group had serum phosphorus <1.78 mmol/L
(P = 0.0001); more patients responded to the experi-
mental drug (defined as a decrease of the serum phos-
phorus level >25% from baseline) in the lanthanum
carbonate group than in the placebo group (56.1% vs.
12.4%; P = 0.0001). The primary efficacy measure and
secondary evaluations all showed that lanthanum car-
bonate achieved better control of serum phosphorus
than placebo.
In patients receiving lanthanum carbonate 1500
(40.3%, 46/114), 2000 (20.2%, 23/114), 2500 (26.3%, 30/
114), or 3000 (13.2%, 15/114) mg and those on placebo,
the proportion achieving the target serum phosphorus
level (≤1.78 mmol/L) was 76.1%, 56.5%, 50.0%, 20.0%,
and 13.3%, respectively.Serum calcium
At the end of the titration period, serum calcium
decreased by 0.03 mmol/L versus the screening period
(from 2.32 to 2.29 mmol/L; P = 0.014). Serum calcium
in the lanthanum carbonate and placebo groups
increased by 0.02 mmol/L and decreased by 0.02 mmol/
L, respectively, at the end of the maintenance phase
(mean difference between groups of 0.04 [95%CI: -0.03,
0.11], P = 0.035). However, the mean serum calcium
level of the lanthanum carbonate-treated group (2.31nthanum carbonate (n=114) Placebo (n=113) P value
.6 (13.0) 48.4 (11.7) 0.761
(52.6) 72 (63.7) 0.090
(47.4) 41 (36.3)
2 (98.2) 111 (98.2) 1.000
(1.7) 2 (1.8)
5.7 (7.7) 165.9 (7.6) 0.674
.9 (12.1) 61.9 (10.8) 0.342
(72.0) 82 (72.6) 0.915
(28.1) 31 (27.4)
9 (0.3) 2.8 (0.3) 0.553
1 (0.3) 4.1 (0.3) 0.460
51.2 (1208.0) 7983.9 (1369.2) 0.839
(3.5) 2 (1.8) 0.683
Table 2 Mean serum phosphorus concentrations at each










0 2.41 (0.50) 2.41 (0.50)
7 1.90 (0.55) 1.93 (0.47)
14 1.72 (0.41) 1.75 (0.51)
21 1.70 (0.53) 1.74 (0.53)
28 1.64 (0.46) 1.71 (0.49) 0.242
42 1.67 (0.51) 2.26 (0.61) <0.001
56 1.79 (0.63) 2.34 (0.56) <0.001
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(ULN) throughout the study.
Ca × P product
Variation in the Ca × P product during the maintenance
period from baseline (time of randomization) is shown in
Table 4. The mean baseline Ca × P in the lanthanum
carbonate-treated and placebo groups was 46.2 and 48.3
mg2/dL2, respectively (P = 0.17). During the second and
fourth weeks of the maintenance phase, patients treated
with lanthanum carbonate had Ca × P product levels of
47.3 and 50.9 mg2/dL2, respectively, both of which were
below 55 mg2/dL2, as recommended by the KDOQI
guideline [9]; whereas in the placebo group, this parameter
increased significantly to 63.6 and 64.9 mg2/dL2, respect-
ively, far exceeding the recommended level. At study end,
the variation of Ca × P product was significantly different
between the treatment groups (4.02 mmol/L vs. 17.46
mmol/L; mean difference between groups −13.44 [95%CI:
-17.87,-9.00], P < 0.001).
Intact parathyroid hormone
At randomization, the difference in the mean iPTH level
between the lanthanum carbonate and placebo-treatedFigure 2 Change in serum phosphorus concentrations at each visit ov
standard deviations.group was not significant (286.4 vs. 315.6 pg/mL; P = 0.48).
Although the difference in the mean iPTH levels between
the two groups remained not significant at the end of the
maintenance phase, a significant difference in variation of
the iPTH level from baseline was observed between the
two groups: 19.60 mmol/L vs. 53.63 mmol/L (mean dif-
ference between groups −34.03 [95%CI: -77.02, 8.96],
P = 0.017).
Analysis of hemodialysis and peritoneal dialysis
subgroups
The patients were divided into hemodialysis (n = 164) and
CAPD (n = 63) subgroups. At the end of the maintenance
period, the increment in serum phosphorus levels was sig-
nificantly higher in placebo-treated patients than in lan-
thanum carbonate-treated individuals in both subgroups
(P < 0.01 and = 0.0001, respectively; Table 3), similar to
the results noted in the whole population.
Safety evaluation
Over the titration period, 157 AEs were reported by 90 of
258 (34.9%) patients enrolled in the study; of these, 101
AEs reported by 40 patients (34.9%) were considered
related to experimental drugs. No SAE or death was
reported. Treatment-emergent AEs for the SS population
during the titration phase are summarized in Table 5. AEs
reported with the highest incidence were GI in nature,
with nausea (15.5%) and vomiting (10.8%) the most com-
mon, accounting for 78.2% of overall events. Other com-
mon GI reactions were abdominal distension (3.1%),
upper abdominal discomfort (1.9%), constipation (1.5%),
abdominal pain (1.2%), and diarrhea (1.2%). The inci-
dences of AEs other than the GI system were all <2%.
The incidence of AEs was lower during the maintenance
phase than the titration phase. There were 34 AEs in 19 of
115 patients (16.5%) in the lanthanum carbonate-treated
group and 11 AEs in 10 of 115 patients (8.7%) in the
placebo-treated group, with incidences of treatment-er the entire study. Data are expressed as means and
Table 3 Mean difference in serum phosphorus compared to baseline at each visit in the maintenance period
Change in serum phosphorus from baseline Lanthanum carbonate Placebo P value Mean(95%CI)
(Lanthanum carbonate- Placebo)
FAS
Day 42 – Day 0
No. of patients (Missing) 113(1) 113(0)
Mean (SD) 0.04(0.52) 0.55(0.63) < 0.001 −0.51(−0.67, -0.36)
Day 56 – Day 0
No. of patients (Missing) 113(1) 113(0)
Mean(SD) 0.15(0.52) 0.63(0.62) < 0.001 −0.48(−0.63, -0.33)
Hemodialysis subgroup
Day 42 – Day 0
No. of patients (Missing) 81(1) 82(0)
Mean(SD) 0.07(0.59) 0.53(0.71) < 0.001 −0.46(−0.66, -0.25)
Day 56 – Day 0
No. of patients (Missing) 81(1) 82(0)
Mean(SD) 0.20(0.57) 0.62(0.68) < 0.001 −0.42(−0.61, -0.22)
Peritoneal dialysis subgroup
Day 42 – Day 0
No. of patients (Missing) 32(0) 31(0)
Mean(SD) −0.06(0.24) 0.61(0.33) 0.000 −0.67(−0.82, -0.53)
Day 56 – Day 0
No. of patients (Missing) 32(0) 31(0)
Mean(SD) 0.01(0.32) 0.65(0.42) 0.000 −0.64(−0.83, -0.46)
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incidence of AEs was higher in the lanthanum carbonate-
treated group than in the placebo-treated group, the dif-
ference was not significant. Treatment-emergent AEs for
the SS population after randomization are shown in
Table 6. Commonly reported AEs were nausea (6.9%),
vomiting (6.1%), and hypocalcemia (1.7%). Apart from
these, each AE reported by the two groups appeared in
only one case.Table 4 Mean difference in laboratory test results at the end
Change from Day 56 to baseline Lanthanum carbonate
Calcium (mmol/L)
No. of patients (Missing) 108(7)
Mean(SD) 0.02(0.32)
Variation of Ca × P (mg2/dl2)
No. of patients (Missing) 108(6)
Mean(SD) 4.02(15.02)
iPTH (pg/ml)
No. of patients (Missing) 109(5)
Mean(SD) 19.60(182.81)
iPTH, intact parathyroid hormone.Three SAEs were reported throughout the entire
course of the study, all within the maintenance period.
One case occurred in the lanthanum carbonate-treated
group and two cases in the placebo-treated group; they
were peritoneal dialysis-related peritonitis, cerebral
infarction, and right cervical fibroma; none was consid-
ered related to experimental drugs. In total, 18 patients
withdrew from the study because of unendurable AEs
or SAEs during treatment phases. Fourteen patientsof the maintenance period
Placebo P value Mean(95% CI)
(Lanthanum carbonate -Placebo)
110(5)
−0.02(0.19) 0.035 0.04(−0.03, 0.11)
109(4)
17.46(17.97) < 0.001 −13.44(−17.87,-9.00)
110(3)
53.63(136.88) 0.017 −34.03(−77.02,8.96)





Symptoms Cases Number Incidence Cases Number Incidence
Nausea 12 8 6.96% 0
Vomiting 11 7 6.09% 0
Constipation 0 1 1 0.87%
Anorexia 1 1 0.87% 0
Hypocalcemia 0 1 1 0.87%
Aggravated
itching
0 1 1 0.87%
Total 24 16 13.91% 3 3 2.61%
Table 5 Summary of drug-related adverse events during
the titration period (no. cases >1)
Symptoms Cases Number Incidence
(n=258)
Nausea 48 40 15.50%
Vomiting 31 28 10.85%
Abdominal distention 7 7 2.71%
Epigastric discomfort 4 4 1.55%
Constipation 3 3 1.16%
Anorexia 4 4 1.55%
Abdominal pain 2 2 0.78%
Total 101 90 34.88%
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maintenance phase. No deaths were reported during the
overall study period.
Discussion
This 8-week, multicenter, double-blind RCT conducted in
mainland China demonstrated that lanthanum carbonate
is efficacious and well tolerated for the treatment of hyper-
phosphatemia in hemodialysis and CAPD patients.
Although calcium-based phosphate binders, either cal-
cium carbonate or calcium acetate, and aluminum hydro-
xide have been widely used to treat hyperphosphatemia in
CKD patients, none of these agents has yet been registered
and approved by the mainland Chinese State Food And
Drug Administration (SFDA). Compared with more devel-
oped areas of China, such as Taiwan and Hong Kong, there
are limited medical resources in mainland China, and
these must serve a large population across a broad terri-
tory [21]. In 2002, nearly 1550 per million people (pmp) in
Taiwan received regular dialysis treatment; this prevalence
was even higher than that in the USA. In the same year,
550 pmp in Hong Kong and only 30 pmp in mainland
China received such treatment [23]. Thus, CKD patients in
mainland China urgently need to have available a validated
and standardized oral phosphate binder to tackle phos-
phate retention [24]. To date, no RCT study from main-
land China has investigated the efficacy and tolerability of
oral phosphate binders. The current phase III study might
contribute to lanthanum carbonate becoming the first cer-
tified oral phosphate-binding agent available for both
hemodialysis and CAPD patients in mainland China.
The present study showed that serum phosphorus con-
centrations of all patients decreased gradually during the
4-week titration phase when they were treated by lan-
thanum carbonate. About three-fifths of patients treated
with lanthanum carbonate achieved target serum phos-
phorus level. The primary efficacy measure and secondary
evaluations all showed that lanthanum carbonate achieved
better control of serum phosphorus than placebo (mean
difference −0.48 mmol/L, median lanthanum carbonatedosage 2000 mg (data not shown)), without significantly
disturbing serum calcium levels. Indeed, the level of serum
calcium in the lanthanum carbonate group decreased by
0.03 mmol/L at the end of the titration phase compared
with the screening period. The findings were not different
between the hemodialysis and peritoneal dialysis sub-
groups. However, the change in the serum phosphorus
concentration from baseline was similar to the level pre-
dicted at study design. Joy et al. [16] reported a mean dif-
ference of −0.6 mmol/L compared to placebo with a
similar median dosage of about 2300 mg of lanthanum
carbonate. In 2005, a study from Taiwan showed that lan-
thanum carbonate could achieve a −0.7 mmol/L mean dif-
ference compared to placebo with a much lower dosage of
750–1500 mg/d [17]. However, the present study sample
was almost double and triple, respectively, of Joy’s study
and Chiang’s study [16,17]. The efficacy of lanthanum car-
bonate should be further tested in future, long-term, RCT
studies.
In patients receiving lanthanum carbonate 1500, 2000,
2500, and 3000 mg, target serum phosphorus (≤1.78
mmol/L) was achieved in 76.1%, 56.5%, 50.0%, and
20.0%, respectively, compared with 13.3% on placebo.
These data suggest that lanthanum carbonate possesses
high phosphorus-binding efficacy with low tablet bur-
den. A single-dose balance study in healthy volunteers
by Martin et al. [25] supports our results in that 1000
mg of lanthanum carbonate could decrease serum phos-
phate by 45% compared with a 21% decrease with 2400
mg of sevelamer carbonate. Daugirdas et al. [26] further
calculated the phosphate binder equivalent doses. In their
reports, 500 mg lanthanum carbonate was equivalent to
750 mg calcium carbonate, 667 mg calcium acetate, and
800 mg sevelamer carbonate, the phosphorus-binding
capacity of which was equal to aluminum carbonate and
not affected by the intestinal pH level [26,27]. Patients
were put on a low-phosphorus diet (800–1000 mg/d) in
the study. We also designed a dietary diary to monitor the
dietary phosphorus intake of each patient (data not
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did not have a specialized nutritionist to collect and calcu-
late the data; so the higher doses prescribed might be
partly due to higher dietary intakes, which could cause
bias to the study. More emphasis should be given to this
in future studies.
The Ca × P product of lanthanum carbonate-treated
patients was below the level (55 mg2/dL2) recommended
by the KDOQI guideline [9] at all visits both in the titra-
tion and maintenance phases, whereas that of placebo-
treated individuals far exceeded it during the maintenance
period. At study endpoint, the Ca × P product of the pla-
cebo group was 14.0 mg2/dL2 higher compared with the
lanthanum carbonate group; the mean difference from
baseline differed significantly (P < 0.001). The change in
the iPTH level was also monitored throughout the study.
The variation in the iPTH level from the time of
randomization (19.60 vs. 53.63 pg/mL) between the two
groups was significantly different (P = 0.017). These results
support previous reports. Currently, bone biopsy cannot be
performed clinically in mainland China. Although the
present study could not demonstrate a beneficial effect of
lanthanum carbonate on renal-associated osteopathy, the
results indicate that lanthanum carbonate helped maintain
the balance among Ca, P, and PTH.
Besides the good efficacy of lanthanum carbonate, the
safety evaluation showed that lanthanum carbonate was
generally safe and well-tolerated in CKD 5D patients.
No deaths and few SAEs were reported throughout the
study. The most frequently reported AEs were GI in
nature, and they improved as patients moved from the
titration to the maintenance phase. A similar pattern
was observed by other researchers [16-20,28,29]. In all,
5.4% and 0.9% of patients withdrew during the titration
and maintenance phases because of side effects of
the experimental drugs. The incidence of AEs was not
significantly different between lanthanum carbonate
and placebo during the maintenance phase. The compli-
ance of the present patients to the experimental drugs
was quite good. Compared with previous double-blind
reports, lanthanum carbonate was better tolerated in the
present study. The present withdrawal rate during the ti-
tration and maintenance phases was the lowest, at only
10.8% and 6.2%, respectively (Additional file 1: Table S1)
[16-20,30,31]. This could be partly due to the strong desire
of CKD 5D patients in mainland China to have better
treatment despite some mild discomfort taking the experi-
mental drugs.
There are some limitations of the present study. Up to
the time the study was launched, no patented calcium or
non-calcium phosphate binder had been approved in
mainland China. Although calcium carbonate was pre-
scribed by nephrologists in some tertiary Chinese hospi-
tals, it had not received certification from the government,and it could not be approved by the ethics committee.
Thus, a calcium or non-calcium containing phosphate
binder could not be used as a control group treatment.
Plasma lanthanum concentrations could not be moni-
tored during the present study. Although lanthanum has
been found to deposit in patients’ bone through biopsy, no
toxicity similar to that of aluminum has been reported so
far [32,33]. Several follow-up studies even showed positive
effects of lanthanum carbonate on bone mineralization.
Although follow-up studies, the longest of which was
≤6 years, detected no toxicity effect of lanthanum carbon-
ate deposition on specific human organs, evaluation of the
long-term tolerability and safety of lanthanum carbonate
in the Chinese populations needs further study [34,35].
The treatment duration of the present study was only
8 weeks. No protective effect of lanthanum carbonate on
patients’ survival or organ calcification was identified.
Lanthanum carbonate has been shown to attenuate vas-
cular calcification both in dialysis patients and in animal
models [36,37]. Further studies should be conducted to
evaluate the effect of lanthanum carbonate on the prog-
nosis of CKD 5D patients in mainland China.
Conclusions
In conclusion, the results of the present study suggest that
lanthanum carbonate is an efficacious and well-tolerated
oral phosphate binder with a mild AE profile in both
hemodialysis and CAPD patients. This agent may provide
an alternative for the treatment of hyperphosphatemia in
CKD 5D patients in mainland China.
Additional file
Additional file 1: Table S1. Summary of double-blind RCT studies on
lanthanum carbonate.
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